United States Blood Cancer Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Blood Cancer Drugs Market size reached USD 63 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 113.5 billion by 2031. The global blood cancer drugs market is expected to exhibit a CAGR of 7.8% during the forecast period 2024-2031.

Recent Mergers and Acquisitions;

United States:

✅ In August 2025, Citius Pharmaceuticals received FDA approval for its blood cancer therapy, Lymphir, targeting relapsed cutaneous T-cell lymphoma. The treatment showed a 36.2% response rate in clinical trials, though it carries a boxed warning for capillary leak syndrome.

✅ In May 2025, Helix BioPharma acquired oncology assets from Laevoroc Immunology AG for CHF 5.3 million. This acquisition enhances Helix's pipeline in blood cancer therapies, focusing on novel treatments for hematologic malignancies.

✅ In March 2024, BeiGene's Brukinsa, in combination with Roche's Gazyva, gained FDA accelerated approval for treating relapsed or refractory follicular lymphoma after at least two prior therapies. This combination demonstrated significant efficacy in mid-stage studies.

✅ In November 2024, Syndax Pharmaceuticals' Revuforj (revumenib) was approved by the FDA for treating acute leukemia with KMT2A translocation in both adults and children. The menin inhibitor achieved a 21% complete remission rate in clinical trials.

Japan:

✅ In July 2025, Asahi Kasei Life Science announced plans to construct a new spinning plant in Nobeoka City, Miyazaki, Japan, to expand production for its Planova line of virus removal filters. The facility is expected to start operations in January 2030.

✅ In May 2025, Servier announced the acquisition of BioNova's acute leukemia asset. This strategic move bolsters Servier's leadership in blood cancers, adding a targeted therapy to its hematology pipeline.

✅ In August 2024, Sanofi's Sarclisa (isatuximab) gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for use in conjunction with VRd to treat newly diagnosed multiple myeloma. This combination therapy aims to improve patient outcomes in early-stage multiple myeloma.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/blood-cancer-drugs-market?sb

Blood Cancer Drugs are therapeutic medications used to treat hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. They include chemotherapy, targeted therapies, immunotherapies, and supportive treatments designed to kill cancer cells, inhibit their growth, and improve patient survival and quality of life.

Key Players:

-> Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.

Growth Forecast Projected:

The Global Blood Cancer Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Blood Cancer Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=blood-cancer-drugs-market

Key Segments:

➥ By Type: Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma
➥ By Drugs Type: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
➥ By Route of Administration: Oral, Parenteral, Others
➥ By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Regional Analysis for Blood Cancer Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Blood Cancer Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Blood Cancer Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/blood-cancer-drugs-market?sb

FAQ

What is the current size of the Blood Cancer Drugs Market?

A: In 2022, the Blood Cancer Drugs Market was valued at USD 63 billion, reflecting its strong industry presence.

Q2: How large is the Blood Cancer Drugs Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Blood Cancer Drugs Market will grow to around USD 113.5 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Blood Cancer Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.